Press release -
Pelago Bioscience AB enters into CETSA™ method licensing agreement with GlaxoSmithKline
Pelago Bioscience AB
has entered into a licensing agreement with GlaxoSmithKline (GSK) for the use
of the Cellular Thermal Shift Assay (CETSA™) for determination and quantification of
drug–target interactions. Under the agreement, Pelago Bioscience grants GSK a license
to the CETSA method for use in research & development.
Topics
- Medicine, Pharmaceuticals
About Pelago Bioscience AB
Spun out from the Karolinska Institute, Stockholm Sweden, Pelago Bioscience AB was founded to provide and develop the patented Cellular Thermal Shift Assay (CETSA™) for use in determination and quantification of drug–target interactions. The company delivers in situ target engagement studies to accelerate preclinical and clinical drug discovery and diagnostics development. Using CETSA data and applications, drug discovery R&D companies will be able to make better and more informed decisions at earlier stages in their projects. This will reduce time and money spent on the wrong compounds and may allow faster development of more efficacious new drugs.
For more information:
Michael Dabrowski, CEO Pelago Bioscience AB
tel. +46 (0)730 715 334, michael@pelagobio.com
